Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$13.06 USD
+0.29 (2.27%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $12.91 -0.15 (-1.15%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Day One Biopharmaceuticals, Inc. [DAWN]
Reports for Purchase
Showing records 1 - 20 ( 70 total )
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; First Ojemda Prescriptions Received
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FIREFLY-1 Lights Pathway for Newly Approved Ojemda (tovorafenib) In r/pLGG
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New RAF on the Block; OJEMDA Gets Accelerated Approval
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
At the DAWN of Tovo?s PDUFA, a Look at Programs on the Horizon Furthers Our Overall Conviction
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for DAWN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financial Results; Updated FIREFLY-1 Data at SNO
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A New DAWN Approaches For Tovo as FDA Sets PDUFA for April ?24
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Receives Priority Review; PDUFA of April 30, 2024
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updated FIREFLY-1 Data; Rolling NDA Submission to FDA Completed
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Continues Its Positive Momentum Toward Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A